总而言之,Prevnar 20/Apexxnar中包含的20种血清型共同导致了目前全球流行的大部分肺炎球菌病。 原文出处:European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults 来源:生物谷 END...
On June 8, 2021, a new 20-valent pneumococcal conjugate vaccine (PCV20, PREVNAR20, Pfizer, Inc.) was licensed for use in adults aged ≥18 years by the US Food and Drug Administration (FDA).#To describe reports to the Vaccine Adverse Event Reporting System (VAERS) after administration of...
V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) specifically designed for adults. It includes eight unique serotypes (15A, 15C [generated from deOAc-15B], 16F, 23A, 23B, 24F, 31 and 35B) not covered by any currently licensed pneumococcal vaccine (Figure 1). This ...
原文出处:European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults
Higher-valent vaccines (which provide coverage for a greater number of disease-causing serotypes) have recently received European Commission approval for use in adults and children. This study examined costs and health benefits associated with the 20-valent pneumococcal conjugate vaccine (PCV20) under...